BC Week In Review | Jan 5, 2018
Clinical News

Actinium reports Phase II data for Actimab-A in AML

Actinium Pharmaceuticals Inc. (NYSE-M:ATNM) reported preliminary data from 13 evaluable patients ages 60 and older with newly diagnosed acute myelogenous leukemia (AML) who were unable to tolerate induction therapy in the Phase II portion of...
BC Week In Review | Oct 3, 2016
Clinical News

Actimab-A: Phase II started

Actinium began an open-label, U.S. Phase II trial to evaluate 2 uCi/kg/fraction doses of Actimab-A given at day 1 and 7 in about 53 patients ages >60. Actinium Pharmaceuticals Inc. (NYSE-M:ATNM), New York, N.Y.  ...
BC Week In Review | Dec 14, 2015
Clinical News

Actimab-A: Additional Phase I/II data

Data from 14 previously untreated AML patients ages >=60 in the Phase I portion of an open-label, U.S. Phase I/II trial showed that 0.5, 1, 1.5 and 2 uCi/kg/fraction doses of Actimab-A plus low-dose cytarabine...
BC Week In Review | Jun 22, 2015
Clinical News

Actimab-A: Additional Phase I/II data

Additional data from 12 previously untreated AML patients >=60 in cohorts 1-3 of an open-label, U.S. Phase I/II trial showed that Actimab-A plus low-dose cytarabine led to 2 cases of complete remission with different degrees...
BioCentury | Jun 8, 2015
Finance

ASCO's early returns

While discussions about value and incremental data from late-stage checkpoint inhibitors dominated this year's American Society of Clinical Oncology meeting in Chicago, it's clear that investors also were on the lookout for - and willing to...
BC Week In Review | Jan 5, 2015
Clinical News

Actimab-A regulatory update

FDA granted Orphan Drug designation to Actimab-A from Actinium to treat acute myelogenous leukemia (AML) in patients ages =60. The product -- actinium-225 attached to the anti- CD33 mAb lintuzumab (HuM195) -- is in Phase...
BC Week In Review | Nov 24, 2014
Clinical News

Actimab-A: Interim Phase I/II data

Interim data from 9 evaluable AML patients ages =60 in an open-label, U.S. Phase I/II trial showed that Actimab-A plus low-dose cytarabine led to a median overall survival (OS) of 5.4 months. In 7 of...
BioCentury | Jun 30, 2014
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Basilea Pharmaceutica AG (SIX:BSLN) fell CHF9.10 to CHF104.90 last week after it said FDA confirmed additional Phase III data would be required to support U.S. approval of ceftobiprole to treat pneumonia. The company...
BC Extra | Jun 25, 2014
Financial News

Actinium, Heron planning follow-ons

Late Tuesday, Actinium Pharmaceuticals Inc. (NYSE-M:ATNM) and Heron Therapeutics Inc. (NASDAQ:HRTX) proposed follow-ons, but neither company disclosed how many shares they plan to issue or how much they expect to raise. Actinium's follow-on is underwritten...
BC Extra | Dec 27, 2012
Financial News

Actinium raises $5.1M ahead of reverse-merger

Actinium Pharmaceuticals Inc. (Newark, N.J.) raised $5.1 million through the sale of about 9.3 million units in the first close of a bridge financing. Each unit comprises a share, a 120-day warrant to purchase a...
Items per page:
1 - 10 of 14